Brian Tinmouth
Förmögenhet: 49 349 $ per 2026-06-30
Förmögenhet: 49 349 $ per 2026-06-30
Brian Philippe Tinmouth is currently an Independent Director at SCYNEXIS, Inc. since 2019.
Formerly, Mr. Tinmouth was Chief Business & Strategy Officer at Mammoth Biosciences, Inc. from 2022 to 2025, Chief Business & Strategy Officer at Pardes Biosciences, Inc. from 2021 to 2022, Vice President & Head-Business Development at Vertex Pharmaceuticals, Inc. from 2013 to 2020, and Senior Manager at Bain & Co., Inc. from 1997 to 2002.
Mr. Tinmouth completed undergraduate studies at Queen's University and earned an MBA from Harvard Business School.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
SCYNEXIS, INC. 0,12 % | 2026-06-26 | 12 125 ( 0,12 % ) | 49 349 $ | 2026-06-30 |
| Företag | Position | Start |
|---|---|---|
| SCYNEXIS, INC. | Direktör/Styrelseledamot | 2019-12-13 |
| Företag | Position | Slut |
|---|---|---|
Mammoth Biosciences, Inc.
Mammoth Biosciences, Inc. Internet Software/ServicesTechnology Services Operates CRISPR-based platform for disease detection | Företagsledare/Principal | 2025-02-01 |
| PARDES BIOSCIENCES, INC. | Företagsledare/Principal | 2022-11-30 |
| VERTEX PHARMACEUTICALS INCORPORATED | Företagsledare/Principal | 2020-03-01 |
Bain & Co., Inc.
Bain & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Provides strategy, marketing, organization, operations, IT and M&A consulting services | Företagsledare/Principal | 2002-01-01 |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 7 |
|---|---|
Vertex Pharmaceuticals, Inc.
Vertex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs for the treatment of cystic fibrosis | Health Technology |
Bain & Co., Inc.
Bain & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Provides strategy, marketing, organization, operations, IT and M&A consulting services | Commercial Services |
SCYNEXIS, Inc.
SCYNEXIS, Inc. Pharmaceuticals: MajorHealth Technology Develops novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections | Health Technology |
Queen's University
Queen's University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Mammoth Biosciences, Inc.
Mammoth Biosciences, Inc. Internet Software/ServicesTechnology Services Operates CRISPR-based platform for disease detection | Technology Services |
Pardes Biosciences, Inc.
Pardes Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops oral antiviral treatment for COVID-19 | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån